Clinical trials: Empagliflozin
SGLT-2 Inhibitor, Atrial Fibrillation
The Effect of SGLT-2 Inhibitor in Patient With Atrial Fibrillation and Diabetes Mellitus
This study was designed to compare the effects on atrial rhythm control between SGLT2 inhibitor and other oral hypoglycemic agents in patients with atrial fibrillation and diabetes mellitus.
- Conditions
- SGLT-2 Inhibitor, Atrial Fibrillation, Diabetes Mellitus, Type 2
- Trial name
- NCT05029115
- Testing
- SGLT2 inhibitor
- Where
- South Korea
- Volunteers
- 716 people
- Sponsor
- Ewha Womans University Mokdong Hospital
T2DM, Diabete Type 2
Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin
Phase 3 study to assess the Efficacy and Safety of CT-L02-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Alogliptin Combination Therapy.
- Conditions
- T2DM, Diabete Type 2, DM
- Trial name
- NCT07093476
- Testing
- Metformin, Alogliptin, empagliflozin
- Where
- South Korea
- Volunteers
- 171 people
- Sponsor
- Celltrion
Diabetes Mellitus, Type 2, Diastolic Dysfunction
Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics
The purpose of the EmDia trial is to compare the effects of empagliflozin with placebo in addition to standard diabetic treatment or dietetic treatment on cardiac diastolic function in patients with type 2 Diabetes mellitus.
- Trial name
- EmDia (NCT02932436)
- Testing
- Empagliflozin
- Where
- Germany
- Volunteers
- 144 people
- Sponsor
- Johannes Gutenberg University Mainz
Diabetes Mellitus, Type 2, Urosepsis
Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients With Type 2 Diabetes
The purpose of this study is to compare the risk of serious adverse events associated with the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in comparison with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors among…
- Conditions
- Diabetes Mellitus, Type 2, Urosepsis, Diabetic Ketoacidosis, Lower Extremity Amputation
- Trial name
- NCT04017221
- Testing
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors, Dipeptidyl peptidase-4 (DPP-4) inhibitors, Other treatment combinations
- Where
- Canada
- Volunteers
- 1,249,636 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Type 2 Diabetes
SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia
To examine the 2-HIT hypothesis that the SGLT2i-induced stimulation of EGP, lipolysis, and ketone production requires the combination of volume depletion plus insulinopenia in T2D individuals.
- Trial name
- NCT07053306
- Testing
- Empagliflozin 25 MG
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Diabetes Mellitus, Type 2
Effects of Empagliflozin-Metformin, Sitagliptin-Metformin, and Metformin on Adipokines in Type 2 Diabetes
This study compared the impacts of empagliflozin-metformin, sitagliptin-metformin, and metformin monotherapy in treatment-naive overweight or obese adults with newly diagnosed type 2 diabetes mellitus in Erbil, Iraq.
- Trial name
- NCT07531108
- Testing
- Empagliflozin-Metformin, Sitagliptin-Metformin, Metformin
- Where
- Iraq
- Volunteers
- 186 people
- Sponsor
- Hawler Medical University
Diabetes Mellitus, Type II
Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin
This study is a randomized, open-label, multiple dosing, crossover study to evaluate the drug-drugs interaction between Lobeglitazone and Empagliflozin in healthy male volunteers
- Trial name
- NCT02854748
- Testing
- Empagliflozin 25mg, Lobeglitazone 0.5mg, Empagliflozin 25mg/Lobeglitazone 0.5mg
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Idiopathic Pulmonary Arterial Hypertension
Empagliflozin in Pulmonary Arterial Hypertension
The aim of the study is to determine whether conducting a randomized placebo-controlled clinical trial is feasible, safe for the patient and whether the treatment is well tolerated in patients with idiopathic pulmonary arterial…
- Trial name
- Emphower PoC (NCT05493371)
- Testing
- Empagliflozin 10 MG
- Where
- Netherlands
- Volunteers
- 8 people
- Sponsor
- Amsterdam UMC, location VUmc
Type 2 Diabetes Mellitus
Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mg
A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-398
- Trial name
- NCT04869800
- Testing
- CKD-398, CKD-501, D745
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
CKD - Chronic Kidney Disease, Diabetes Mellitus Type 2
Evaluation of the Risk of Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus
The goal of this study, performed entirely with computer programs, is to learn if using a combination of two drugs works better than using one alone, in the treatment of people with chronic kidney disease and type 2 diabetes…
- Trial name
- NCT07719621
- Where
- Spain
- Volunteers
- 100,000 people
- Sponsor
- Aeterna Medical Solutions SL
Diabetic Neuropathy Peripheral
Empagliflozin in Treatment of Peripheral Diabetic Neuropathy
The aim of the study is to investigate the possible protective effect of empagliflozin in patients with type 2 diabetes mellitus with diabetic peripheral neuropathy and not on SGLT2 inhibitors treatment.
- Trial name
- NCT05977465
- Testing
- Empagliflozin 25 MG
- Where
- Egypt
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Tanta University
Pulmonary Arterial Hypertension
A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension
The goal of this clinical trial is to learn if empagliflozin works to treat patients with pulmonary arterial hypertension. It will also learn about the safety of empagliflozin.
- Trial name
- NCT06554301
- Testing
- empagliflozin in treatment pulmonary aerterial hypertension
- Where
- China
- Volunteers
- 72 people
- Sponsor
- China National Center for Cardiovascular Diseases
Chronic Kidney Diseases, MAFLD
Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.
This project aims to investigate how Chronic Kidney Disease (CKD) develops and progresses in patients who also have Non-Alcoholic Fatty Liver Disease (NAFLD) and to evaluate whether oral semaglutide (a GLP-1 receptor agonist) can…
- Trial name
- NCT07391267
- Testing
- Semaglutide Oral Tablet, Standard medical treatment
- Where
- India
- Volunteers
- 90 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Insulin Resistance - Type A, Insulin Resistance - Type B
A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance
A multicenter, open-label, single-arm study with regard to the efficacy and safety of empagliflozin in patients with refractory diabetes mellitus with insulin resistance
- Conditions
- Insulin Resistance - Type A, Insulin Resistance - Type B, Lipoatrophic Diabetes Mellitus, Insulin Resistance Syndrome
- Trial name
- EMPIRE-01 (NCT04018365)
- Testing
- Empagliflozin Tablets
- Where
- 5 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Kobe University
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
This trial is conducted globally. The aim of this trial is to investigate Efficacy and Safety of Oral Semaglutide versus Empagliflozin in Subjects with Type 2 Diabetes Mellitus.
- Trial name
- PIONEER 2 (NCT02863328)
- Testing
- semaglutide, empagliflozin
- Where
- 106 sites in United States, Argentina and 10 more
- Volunteers
- 822 people
- Sponsor
- Novo Nordisk A/S
Healthy
Bioavailability and Pharmacokinetics of BI 10773 Tablet in Healthy Male Volunteers
Trial to assess the effect of food on the pharmacokinetics and the extent of absorption of a single dose BI 10773 tablet in healthy subjects
- Trial name
- NCT02172209
- Testing
- BI 10773
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Obesity, Non-diabetic Chronic Kidney Disease
SGLT2 Inhibitors in Glomerular Hyperfiltration
Glomerular hyperfiltration is a major risk factor for accelerated glomerular filtration rate (GFR) decline and renal and cardiovascular events despite optimized conservative therapy with blood pressure and blood glucose (in…
- Trial name
- EMPATHY (NCT04143581)
- Testing
- Empagliflozin 10 MG
- Sponsor
- Mario Negri Institute for Pharmacological Research
Dyslipidemia Associated With Type II Diabetes Mellitus, Diabetes Mellitus, Type 2
EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial
Based on the current evidence, empagliflozin could reduce cardiovascular morbidity and mortality in Diabetes Mellitus Type 2 (T2DM).
- Conditions
- Dyslipidemia Associated With Type II Diabetes Mellitus, Diabetes Mellitus, Type 2, Hypertension Arterial
- Trial name
- EXCEED-BHS3 (NCT03932721)
- Testing
- Evolocumab 140 MG/ML
- Where
- Brazil
- Volunteers
- 110 people
- Sponsor
- University of Campinas, Brazil
Diabetes Mellitus, Type 2
12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
The objective is to investigate the efficacy, safety and pharmacokinetics of three different doses of BI 10773 compared to placebo given for 12 weeks in patients with type 2 diabetes mellitus with insufficient glycemic control.
- Trial name
- NCT00789035
- Testing
- BI 10773, metformin
- Where
- 74 sites in Argentina, Croatia and 11 more
- Volunteers
- 408 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen
In the treatment of type 2 diabetes (T2D), the number of patients requiring combination therapy of oral antidiabetic agents (OADs) is more than 70%.
- Trial name
- NCT04013581
- Testing
- TZD group, SGLT-2 group
- Where
- South Korea
- Volunteers
- 121 people
- Sponsor
- Yonsei University